New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Lilly presented new ESMO 2026 data showing durable first-line activity for its investigational KRAS G12C inhibitor olomorasib in KRAS G12C-mutant non-small cell lung cancer, with median PFS and duration of response not yet reached after ~21 months of follow-up in the pembrolizumab combination. In the chemoimmunotherapy arm, olomorasib plus pembrolizumab, pemetrexed and platinum achieved a 62% overall response rate with a 14.5-month median duration of response in 77 patients.
Key figures
- Drug Name
- olomorasib (LY3537982)
- Phase Of Trial
- Phase 1/2 LOXO-RAS-20001 and Phase 3 SUNRAY-01 safety lead-in
- Phase3 data timing
- first half of 2027
- Immunotherapy arm patients
- 85
- Kras g12c prevalence nsclc
- 13%
- Orr chemoimmunotherapy arm
- 62%
- Median pfs immunotherapy arm
- not reached
- Median dor chemoimmunotherapy
- 14.5 months
- Median pfs chemoimmunotherapy
- 11.6 months
- Chemoimmunotherapy arm patients
- 77
- Median followup immunotherapy arm
- 20.7 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.